Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EBITDA (2016 - 2025)

Historic EBITDA for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $153.6 million.

  • Neurocrine Biosciences' EBITDA rose 6271.19% to $153.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $485.9 million, marking a year-over-year increase of 4286.97%. This contributed to the annual value of $485.9 million for FY2025, which is 4286.97% up from last year.
  • According to the latest figures from Q4 2025, Neurocrine Biosciences' EBITDA is $153.6 million, which was up 6271.19% from $210.2 million recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' EBITDA registered a high of $210.2 million during Q3 2025, and its lowest value of -$71.4 million during Q1 2023.
  • Its 4-year average for EBITDA is $79.1 million, with a median of $82.5 million in 2023.
  • As far as peak fluctuations go, Neurocrine Biosciences' EBITDA skyrocketed by 15560.22% in 2024, and later tumbled by 7204.03% in 2025.
  • Over the past 4 years, Neurocrine Biosciences' EBITDA (Quarter) stood at $22.2 million in 2021, then surged by 604.5% to $156.4 million in 2023, then tumbled by 39.64% to $94.4 million in 2024, then skyrocketed by 62.71% to $153.6 million in 2025.
  • Its EBITDA stands at $153.6 million for Q4 2025, versus $210.2 million for Q3 2025 and $111.0 million for Q2 2025.